Somatic mutations in SERPINB3, a gene encoding a protein of the serpin family of serine protease inhibitors, were reported to predict improved survival from treatment with anti-CTLA4 therapy in two independent cohorts of patients with melanoma [35]. Here, CTLA4 is linked to melanoma.